Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
After finishing at $12.54 in the prior trading day, Entrada Therapeutics Inc (NASDAQ: TRDA) closed at $12.69, up 1.20%. In other words, the price has increased by $1.20 from its previous closing price. On the day, 0.11 million shares were traded. TRDA stock price reached its highest trading level at $12.73 during the session, while it also had its lowest trading level at $12.49.
Ratios:
Our goal is to gain a better understanding of TRDA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.59 and its Current Ratio is at 6.59. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, ROTH MKM on December 06, 2024, initiated with a Buy rating and assigned the stock a target price of $29.
On January 05, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $22.
On April 03, 2023, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $25.H.C. Wainwright initiated its Buy rating on April 03, 2023, with a $25 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 10 ’24 when MPM BIOVENTURES 2018, L.P. sold 22,935 shares for $20.77 per share. The transaction valued at 476,360 led to the insider holds 4,402,849 shares of the business.
MPM BIOVENTURES 2018, L.P. sold 21,787 shares of TRDA for $440,751 on Dec 11 ’24. The 10% Owner now owns 4,381,062 shares after completing the transaction at $20.23 per share. On Dec 10 ’24, another insider, MPM BioVentures 2014, L.P., who serves as the 10% Owner of the company, sold 22,935 shares for $20.77 each. As a result, the insider received 476,360 and left with 4,402,849 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TRDA now has a Market Capitalization of 474859776 and an Enterprise Value of 61264108. As of this moment, Entrada’s Price-to-Earnings (P/E) ratio for their current fiscal year is 7.96. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.21 while its Price-to-Book (P/B) ratio in mrq is 1.12. Its current Enterprise Value per Revenue stands at 0.285 whereas that against EBITDA is 0.999.
Stock Price History:
The Beta on a monthly basis for TRDA is -0.13, which has changed by -0.18991381 over the last 52 weeks, in comparison to a change of 0.23631513 over the same period for the S&P500. Over the past 52 weeks, TRDA has reached a high of $21.79, while it has fallen to a 52-week low of $11.35. The 50-Day Moving Average of the stock is -29.47%, while the 200-Day Moving Average is calculated to be -20.71%.
Shares Statistics:
The stock has traded on average 121.26K shares per day over the past 3-months and 130570 shares per day over the last 10 days, according to various share statistics. A total of 37.40M shares are outstanding, with a floating share count of 21.88M. Insiders hold about 41.53% of the company’s shares, while institutions hold 53.15% stake in the company. Shares short for TRDA as of 1735603200 were 1837237 with a Short Ratio of 15.15, compared to 1732838400 on 1526416. Therefore, it implies a Short% of Shares Outstanding of 1837237 and a Short% of Float of 7.8600004000000006.
